Neurotrope 10-K 10 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 06, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	Neurotrope, Inc.
Entity Central Index Key	1,513,856
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 15,854,174
Trading Symbol	NTRP
Entity Common Stock, Shares Outstanding		7,448,823

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 25,773,533	$ 11,230,637
Prepaid expenses	138,711	1,489,851
Subscription receivable	0	2,761
TOTAL CURRENT ASSETS	25,912,244	12,723,249
Fixed Assets, net of accumulated depreciation	55,198	59,175
TOTAL ASSETS	25,967,442	12,782,424
CURRENT LIABILITIES
Accounts payable	2,167,413	449,875
Accrued expenses	190,744	141,525
Accrued expenses - related party	4,609	389,058
Note payable	0	10,511
TOTAL CURRENT LIABILITIES	2,362,766	990,969
Commitments and contingencies
SHAREHOLDERS' DEFICIT
Common stock - 12,500,000 shares authorized, $.0001 par value; 6,754,547 shares issued and outstanding at December 31, 2016; 1,536,570 shares issued and outstanding at December 31, 2015	676	154
Additional paid-in capital	73,648,737	27,700,651
Accumulated deficit	(50,044,737)	(27,724,224)
TOTAL SHAREHOLDERS' DEFICIT	23,604,676	(23,419)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	25,967,442	12,782,424
Series B Convertible Redeemable Preferred Stock [Member]
CONVERTIBLE REDEEMABLE PREFERRED STOCK
Convertible redeemable preferred stock, Series B, $.0001 par value, 333,333 shares authorized; 262,349.4 shares issued and outstanding at December 31, 2015. Liquidation preference of $15,740,963 plus dividends accruable of $279,824 at December 31, 2015.	$ 0	$ 11,814,874

Consolidated Balance Sheets _Pa

Consolidated Balance Sheets [Parenthetical] - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	12,500,000	12,500,000
Common stock, shares issued	6,754,547	1,536,570
Common stock, shares outstanding	6,754,547	1,536,570
Series B Convertible Redeemable Preferred Stock [Member]
Convertible redeemable preferred stock, par value (in dollars per share)		$ 0.0001
Convertible redeemable preferred stock, shares authorized		333,333
Convertible redeemable preferred stock, shares issued		262,349.4
Convertible redeemable preferred stock, shares outstanding		262,349.4
Convertible redeemable preferred stock, Liquidation Preference, Value (in dollars)		$ 15,740,963
Dividends Payable (in dollars)		$ 279,824

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
OPERATING EXPENSES:
Research and development - related party	$ 1,028,915	$ 2,023,595
Research and development	5,603,989	2,180,263
General and administrative - related party	59,500	804,022
General and administrative	3,435,707	3,714,943
Stock-based compensation - related party	752,695	175,752
Stock-based compensation	2,051,832	547,182
TOTAL OPERATING EXPENSES	12,932,638	9,445,757
OTHER INCOME:
Interest income	8,436	4,222
Net loss before income taxes	(12,924,202)	(9,441,535)
Provision for income taxes	0	0
Net loss	(12,924,202)	(9,441,535)
Preferred Stock dividends	0	(279,824)
Net loss attributable to common shareholders	$ (12,924,202)	$ (9,721,359)
PER SHARE DATA:
Basic and diluted loss per common share (in dollars per share)	$ (5.69)	$ (11.64)
Basic and diluted weighted average common shares outstanding (in shares)	2,272,000	835,200

Consolidated Statement of Chang

Consolidated Statement of Changes in Shareholders' Deficit - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014	$ (11,652,303)	$ 75	$ 6,630,311	$ (18,282,689)
Balance (in shares) at Dec. 31, 2014		751,065
Conversion of preferred stock to common stock	18,524,163	$ 67	18,524,096	0
Conversion of preferred stock to common stock (in shares)		667,594
Issuance of additional common stock upon Series A anti-dilution	0	$ 10	(10)	0
Issuance of additional common stock upon Series A anti-dilution (in shares)		100,253
Stock based compensation	722,934	$ 0	722,934	0
Exercise of common stock warrants	5,651	$ 2	5,649	0
Exercise of common stock warrants (in shares)		17,658
Issuance of common stock warrants	1,817,671	$ 0	1,817,671	0
Net loss	(9,441,535)	0	0	(9,441,535)
Balance at Dec. 31, 2015	(23,419)	$ 154	27,700,651	(27,724,224)
Balance (in shares) at Dec. 31, 2015		1,536,570
Conversion of preferred stock to common stock	11,814,874	$ 85	11,814,789	0
Conversion of preferred stock to common stock (in shares)		847,371
Issuance of Common Stock in Private Placement	21,759,717	$ 383	21,759,334
Issuance of Common Stock in Private Placement (in shares)		3,828,754
Stock based compensation	2,804,527	$ 0	2,804,527	0
Exercise of common stock warrants	173,179	$ 54	173,125	0
Exercise of common stock warrants (in shares)		541,189
Shares issued for stock split rounding		662
Revaluation of investor warrants	0		9,396,311	(9,396,311)
Net loss	(12,924,202)	$ 0	0	(12,924,202)
Balance at Dec. 31, 2016	$ 23,604,676	$ 676	$ 73,648,737	$ (50,044,737)
Balance (in shares) at Dec. 31, 2016		6,754,547

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (12,924,202)	$ (9,441,535)
Adjustments to reconcile net loss to net cash used by operating activities
Stock based compensation	2,804,527	722,934
Depreciation expense	6,923	6,270
Change in assets and liabilities
Decrease (increase) in prepaid expenses	1,351,140	(1,392,778)
Decrease (Increase) in subscription receivable	2,761	(2,761)
Increase (decrease) in accounts payable	1,717,538	(328,878)
Increase (decrease) in accrued expenses	49,219	(168,910)
Total adjustments	5,547,659	(875,065)
Net Cash Used in Operating Activities	(7,376,543)	(10,316,600)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(2,946)	(11,827)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock, net of transaction costs	21,759,717	0
Issuance of preferred stock, net of transaction costs	0	13,532,546
Proceeds from note payable	0	28,904
Repayments on note payable	(10,511)	(18,394)
Proceeds from exercise of common stock warrants	173,179	5,651
Net Cash Provided by Financing Activities	21,922,385	13,548,707
NET INCREASE IN CASH	14,542,896	3,220,280
CASH AT BEGINNING OF YEAR	11,230,637	8,010,357
CASH AT END OF YEAR	25,773,533	11,230,637
DISCLOSURE OF NON-CASH FINANCING ACTIVITIES:
Dividend deemed from warrant revaluation	$ 9,396,311	$ 0
Conversion of convertible redeemable preferred stock to common stock	11,814,874	18,524,163
Accounts Payable [Member]
Change in assets and liabilities
Increase (Decrease) in Due to Related Parties, Total	$ 0	$ (200,000)
Accrued Liabilities [Member]
Change in assets and liabilities
Increase (Decrease) in Due to Related Parties, Total	$ (384,449)	389,058
Series B Units [Member]
Adjustments to reconcile net loss to net cash used by operating activities
Consulting services paid by issuance of Series B units		$ 100,000

Organization and Nature of Plan

Organization and Nature of Planned Business:	12 Months Ended
	Dec. 31, 2016
GENERAL ORGANIZATION AND BUSINESS [Abstract]
Nature of Operations [Text Block]	Note 1 – Organization and Nature of Planned Business : Neurotrope BioScience was incorporated in Delaware on October 31, 2012. Neurotrope BioScience was formed to advance new therapeutic and diagnostic technologies in the field of neurodegenerative disease, primarily Alzheimer’s disease (“AD”). Neurotrope BioScience is collaborating with Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”), a related party, in this process. The exclusive rights to certain technology were licensed by CRE to the Company on February 28, 2013 (see Note 5). On August 23, 2013, a wholly-owned subsidiary of Neurotrope, Inc. (formerly “BlueFlash Communications, Inc.”), Neurotrope Acquisition, Inc., a corporation formed in the State of Nevada on August 15, 2013, merged with and into Neurotrope BioScience (the “Reverse Merger”). Neurotrope BioScience was the surviving corporation in the Reverse Merger and became the Company’s wholly-owned subsidiary. All of the outstanding Neurotrope BioScience common stock was converted into shares of Neurotrope, Inc. common stock, par value $ 0.0001 The transaction was accounted for as a reverse merger and recapitalization with Neurotrope BioScience as the acquirer for financial reporting purposes and Neurotrope, Inc. as the acquired company. Consequently, the assets and liabilities and the operations that are reflected in the historical financial statements are those of Neurotrope BioScience and are recorded at the historical cost basis of Neurotrope BioScience, and the consolidated financial statements after completion of the Reverse Merger include the assets and liabilities of Neurotrope BioScience and Neurotrope, Inc., and the historical operations of Neurotrope, Inc. and Neurotrope BioScience from the closing date. As a result of the Reverse Merger, Neurotrope, Inc. discontinued its pre-Reverse Merger business and acquired the business of Neurotrope BioScience, which it is continuing to operate through Neurotrope BioScience. The common stock of Neurotrope, Inc. is traded under the ticker symbol “NTRP.” As of March 6, 2017, we had approximately $ 24.1

Summary of Significant Accounti

Summary of Significant Accounting Policies:	12 Months Ended
	Dec. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Significant Accounting Policies [Text Block]	Note 2 – Summary of Significant Accounting Policies : The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2016, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation. December 31, December 31, 2016 2015 Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (14,518) (7,595) Property and equipment, net $ 55,198 $ 59,175 Depreciation expense for the years ended December 31, 2016 and 2015 was $ 6,923 6,270 All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at December 31, 2016 and 2015. Basic earnings (loss) per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options and warrants subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of December 31, 2016 and 2015. At December 31, 2016 and 2015, the number of shares underlying options and warrants that were anti-dilutive were approximately $ 6.9 4.5 Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions for generally three years from the date of filing. The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives. The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option expense is recognized over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model. In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation

Contractual Commitments_

Contractual Commitments:	12 Months Ended
	Dec. 31, 2016
Contractual Commitments [Abstract]
Contractual Commitments [Text Block]	Note 3 – Contractual Commitments : On September 4, 2014, the Company entered into a long-term lease for 4,000 The lease commenced on September 1, 2014 and expires on December 1, 2017 and has two (2) one-year renewal options. 88,000 136,100 Pursuant to the Ramat Separation Agreement, Mr. Ramat received his current salary and benefits through the Termination Date, except that his salary was reduced by $ 10,000 200,000 50,000 In connection with the resignations of each of Mr. Freiman and Mr. Haft from the Board, the Company entered into a Director Separation Agreement, dated August 4, 2016, with each of Mr. Freiman and Mr. Haft (the “Director Separation Agreements”). Pursuant to such Director Separation Agreements, each of Mr. Freiman and Mr. Haft’s (i) outstanding unvested stock options, totaling 18,738 In addition, on August 4, 2016, the Company entered into a consulting agreement with SM Capital Management, LLC (“SMCM”), a limited liability company owned and controlled by Mr. Joshua Silverman (the “Consulting Agreement”). Pursuant to the Consulting Agreement, SMCM shall provide consulting services which shall include, but not be limited to, providing business development, financial communications and management transition services, for a one-year period, subject to annual review thereafter. SMCM’s annual consulting fee is $ 120,000

Collaborative Agreements_

Collaborative Agreements:	12 Months Ended
	Dec. 31, 2016
Collaborative Agreements [Abstract]
Collaborative Agreements [Text Block]	Note 4 – Collaborative Agreements : On May 12, 2014, the Company entered into a license agreement (the “Stanford Agreement”) with The Board of Trustees of The Leland Stanford Junior University (“Stanford”), pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. During the year ended December 31, 2016, the Company paid Stanford the annual maintenance fee of $ 10,000 On January 19, 2017, the Company entered into a second license agreement with Stanford. See Footnote 10 “Subsequent Events” for additional information. On May 15, 2014, the Company entered into an agreement with a contract research organization (“CRO”) to conduct a clinical trial relating to AD. The Company had agreed to pay fees to the CRO totaling $ 715,159 657,238 150,000 837,112 39,200 On October 9, 2015, Neurotrope BioScience executed a Services Agreement (the “Services Agreement”) with WCT, effective as of August 31, 2015. The Agreement relates to services for Neurotrope BioScience’s Phase 2 clinical study assessing the safety, tolerability and efficacy of bryostatin in the treatment of moderately severe to severe AD (the “Study”). Pursuant to the terms of the Services Agreement, WCT will provide services to enroll approximately one hundred and fifty (150) Study subjects. The first Study site was initiated during the fourth quarter of 2015. The total estimated budget for the services, including pass-through costs, was approximately $ 11.6 200,000 On July 27, 2016, the Company received approval of the institutional review board (“IRB”) for its amended protocol submitted on July 21, 2016 to the U.S. Food and Drug Administration (the “FDA”) relating to the Phase 2 clinical trial of the Company’s lead drug candidate, bryostatin-1, for the treatment of advanced AD, which amended protocol eliminates the second, exploratory, study period following the first 12 weeks of treatment. The primary objective is the assessment of safety and tolerability of bryostatin to occur at 13 weeks, which has not been changed with this amendment. The secondary objective is to assess efficacy, also at week 13. The amendment to cut the exploratory part of the study was made for business reasons in order to provide earlier completion of the study and for the planning of future studies. The changes to the study design were not due to any safety concerns. The cost savings from this amendment is approximately $ 2 On November 11, 2015, Neurotrope BioScience paid WCT $ 1,875,861 928,000 268,000 680,000 9.5 1.6 Also, in connection with the execution of the Services Agreement, Neurotrope BioScience received consent and entered into a Statement of Work pursuant to its CRE License Agreement (see Note 5 below).

Related Party Transactions and

Related Party Transactions and Licensing / Research Agreements:	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 5 – Related Party Transactions and Licensing / Research Agreements : As of December 31, 2016, James Gottlieb, a director of the Company, served as a director of CRE, and Shana Phares, also a director of the Company, served as President and Chief Executive Officer of CRE. William Singer was the president of CRE until April 26, 2016. CRE is a stockholder of a corporation, Neuroscience Research Ventures, Inc. (“NRVI”), which owned 3.9 Effective October 31, 2012, Neurotrope BioScience executed a Technology License and Services Agreement (the “TLSA”) with CRE, a related party, and NRV II, LLC (“NRV II”), another affiliate of CRE, which was amended by Amendment No. 1 to the TLSA as of August 21, 2013. As of February 4, 2015, the parties entered into an Amended and Restated Technology License and Services Agreement (the “CRE License Agreement”). The CRE License Agreement amended and restated the TLSA, as amended. Under the terms of the CRE License Agreement, CRE provides research services and has granted Neurotrope BioScience the exclusive and nontransferable world-wide, royalty-bearing right, with a right to sublicense (in accordance with the terms and conditions described below), under CRE’s and NRV II’s respective right, title and interest in and to certain patents and technology owned by CRE or licensed to NRV II by CRE as of or subsequent to October 31, 2012, to develop, use, manufacture, market, offer for sale, sell, distribute, import and export certain products or services for therapeutic applications for AD and other cognitive dysfunctions in humans or animals (the “Field of Use”). Additionally, the TLSA specifies that all patents that issue from a certain patent application, shall constitute licensed patents and all trade secrets, know-how and other confidential information claimed by such patents constitute licensed technology under the CRE License. The CRE License Agreement terminates on the later of the date (a) the last of the licensed patent expires, is abandoned, or is declared unenforceable or invalid or (b) the last of the intellectual property enters the public domain. After the initial Series A Stock financing, the CRE License Agreement required Neurotrope BioScience to enter into scope of work agreements with CRE as the preferred service provider for any research and development services or other related scientific assistance and support services. In addition, the CRE License Agreement requires the Company to pay CRE a “Fixed Research Fee” of $ 1 25,000,000 2 5 5 On November 12, 2015, Neurotrope BioScience, CRE, and NRV II entered into an amendment (the “Amendment”) to the TLSA pursuant to which CRE granted rights in certain technology to Neurotrope BioScience. Under the Amendment, the “Advances on Future Royalties” section of the TLSA was amended and restated to (i) eliminate the requirement that Neurotrope BioScience pay CRE prepaid royalties equal to five percent ( 5 2.5 Pursuant to the CRE License Agreement, on February 4, 2015, Neurotrope BioScience and CRE entered into a new Statement of Work and Account Satisfaction Agreement (the “February 2015 SOW”). The February 2015 SOW was effective as of October 1, 2014 and ended on September 30, 2015. In consideration for the February 2015 SOW, CRE agreed to (a) use commercially reasonable efforts to enroll at least four (4) additional compassionate use or expanded access patients, in trials of CRE’s Alzheimer’s therapeutic drug platform during the term of the SOW, (b) perform certain services requested by Neurotrope BioScience for the further development of CRE’s Alzheimer’s therapeutic drug platform, (c) perform certain services for the further development of CRE’s Alzheimer’s diagnostic test, (d) to the extent permitted by applicable law, transfer all of its rights and regulatory obligations, except for those relating to the compassionate use expanded access trials, associated with CRE’s Investigative New Drug Application (“IND”) 71,276 to Neurotrope BioScience, (e) conduct initial research on the application of its PKCε platform to treat Fragile X disease, (f) conduct initial research on polyunsaturated fatty acid derivatives for the purpose of developing a commercially usable PKCε activator, and (g) provide assistance, advice and other similar services to Neurotrope BioScience regarding Neurotrope BioScience’s analysis of bryologs pursuant to Neurotrope BioScience’s agreement with Stanford University, for the purpose of developing a commercially usable PKCε activator. Under the CRE License Agreement, Neurotrope BioScience received a license to certain technology, including rights relating to an in vitro test system based on examination of skin cells intended to predict the presence of AD in humans (the “AD Diagnostic Test”). Further, under the February 2015 SOW, Neurotrope BioScience’s rights to the technology associated with the AD Diagnostic Test automatically reverted to CRE based on certain contractual conditions on July 10, 2015 and, accordingly, Neurotrope Bioscience no longer has any rights under the CRE License Agreement for diagnostic applications using the CRE patent portfolio or technology. The remaining terms and conditions of the CRE License Agreement, including the license of technology associated with Neurotrope BioScience’s PKC activator research (such as bryostatin), remain in full force and effect, in accordance with the conditions thereof. For the year ended December 31, 2015, Neurotrope BioScience incurred $ 2,052,595 14,558 On November 12, 2015, Neurotrope BioScience and CRE entered into a new statement of Work Agreement (the “November 2015 SOW Agreement”) pursuant to the TLSA. The November 2015 SOW Agreement is effective as of November 1, 2015 and continues until December 31, 2016. Pursuant to the November 2015 SOW Agreement, Neurotrope BioScience agreed to pay CRE $ 1,166,666 83,333 1 On July 28, 2016, CRE filed a petition for Chapter 11 Reorganization in the United States Bankruptcy Court for the Northern District of West Virginia. As part of the bankruptcy filing, CRE asked the Bankruptcy Court to reject certain executory contracts including employment agreements with a number of its researchers and other personnel, including, without limitation, Dr. Daniel Alkon, who is the Company’s Chief Scientific Officer and was also the former scientific director of CRE, and who led a team of CRE scientists who are involved on behalf of CRE in support of the Neurotrope-CRE License Agreement. CRE has not requested that the Neurotrope-CRE License Agreement itself be rejected. The Company does not believe that CRE, as a matter of law, has a right to terminate the Neurotrope-CRE License Agreement as a result of the bankruptcy filing and have been advised by CRE’s representatives that there will be no action regarding the Neurotrope-CRE License and that CRE intends to meet all of its obligations in support of the Company’s work. On September 23, 2016, the United States Bankruptcy Court for the Northern District of West Virginia entered an order approving the sale of a substantial amount of CRE's assets to West Virginia University. The Court also entered an order approving a settlement agreement between Dr. Alkon, CRE and West Virginia University. As part of the asset sale, CRE sold the BRNI name and all derivatives to West Virginia University. Consequently, the Board of CRE resolved on September 28, 2016 to change its name to Cognitive Research Enterprises, Inc.

Income Taxes_

Income Taxes:	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 6 – Income Taxes : The Company incurred a net operating loss for income tax purposes of approximately $ 32.5 11.0 1.1 Under Section 382 of the Internal Revenue Code of 1986, as amended, changes in the Company's ownership may limit the amount of its net operating loss carryforwards that could be utilized annually to offset future taxable income, if any. This limitation would generally apply in the event of a cumulative change in ownership of the Company of more than 50% within a three-year period. The Company has not completed a study to assess whether an ownership change for purposes of Section 382 has occurred, or whether there have been multiple ownership changes since the Company's inception, due to the significant costs and complexities associated with such study.

Common Stock_

Common Stock:	12 Months Ended
	Dec. 31, 2016
STOCKHOLDERS' EQUITY [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 7 – Common Stock: During the year ended December 31, 2016, all of the Company’s 262,349.4 0.0001 847,371 541,189 0.32 541,189 On April 12, 2016, the stockholders of the Company approved an increase in the number of authorized shares of Common Stock to 12,500,000 150 November 2016 Private Placement In a November 2016 private placement, the Company sold 3,828,754 12.80 6.40 24.5 In connection with the November 2016 Private Placement, on November 17, 2016, the Company filed with the Secretary of State of the State of Nevada an Amendment to its Certificate of Designations, Preferences and Rights of Series B Preferred Stock (the “Series B COD Amendment”), originally filed November 13, 2015 with the Secretary of State of the State of Nevada, as corrected by the Certificate of Correction filed November 19, 2015 with the Secretary of State of the State of Nevada (as so corrected, the “Certificate of Designation”). The Series B COD Amendment (i) provided that the Company’s entry into a binding securities purchase agreement, by and among the Company and the investors signatory thereto, in connection with a private placement of the Company’s common stock and warrants, that results in at least $ 8,000,000 18.56 255,450.4 825,812 Pursuant to the purchase agreement entered into in connection with November 2016 Private Placement, the Company agreed to reduce the exercise prices of certain of its outstanding warrants to purchase shares of common stock that were issued in connection with the November 2015 Private Placement. Effective as of November 18, 2016, the exercise price of each of the Series A Warrants and the Series C Warrants was reduced to $ 0.32 32.00 9.4 In connection with the Offering, pursuant to a Placement Agency Agreement, dated October 13, 2016 (the “Placement Agency Agreement”), among the Company, Katalyst Securities LLC and GP Nurmenkari Inc. (the “Placement Agents”), the Company has agreed to pay the Placement Agents (i) a cash fee at each closing under the Purchase Agreement equal to ten percent ( 10 10 6.40 Under the Placement Agency Agreement, the Company agreed to amend certain warrants previously issued to the Placement Agents. Immediately following the receipt of at least $8,000,000 of gross proceeds as part of the Offering, the exercise price of the 70,119 0.32 10,000,000 41,416 0.32

Stock Options_

Stock Options:	12 Months Ended
	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Stock Option Note Disclosure [Text Block]	Note 8 – Stock Options : The Board adopted, with the approval of the Company’s stockholders, the 2013 Equity Incentive Plan (the “2013 Plan”), which provided for the issuance of incentive awards of up to 218,750 On July 23, 2014, the Company’s Board approved an increase in the total number of shares available under the 2013 Plan by 93,750 312,500 Effective on November 21, 2016, the Company amended the 2013 Plan pursuant to an Amendment to the Neurotrope, Inc. 2013 Equity Incentive Plan (the “Equity Incentive Plan Amendment”) to increase the number of shares of Common Stock available for issuance under the Plan to 685,325 Option Grants Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in thousands) Options outstanding at January 1, 2016 268,217 $ 42.24 7.5 $ 0 Options granted 424,390 $ 11.56 Less options forfeited (16,170) $ 20.29 Less options expired/cancelled (625) $ 56.32 Less options exercised - $ - Options outstanding at December 31, 2016 675,812 $ 23.54 8.9 $ 0 Options exercisable at December 31, 2016 436,357 $ 28.71 8.3 $ 0 In connection with the resignations of Mr. Ramat as President, Chief Executive Officer and director and of Mr. Freiman and Mr. Haft as directors, the Company entered into separation agreements, dated August 4, 2016, with each of Mr. Ramat, Mr. Freiman and Mr. Haft. Pursuant to such separation agreements, each of Mr. Ramat’s, Mr. Freiman’s and Mr. Haft’s (i) outstanding unvested stock options, totaling 40,511 500,000 Stock Options Stock Options Outstanding Exercisable Weighted Avg. Weighted Avg. Weighted Avg. Range of Number of Contractual Life Exercise Number of Exercise Exercise Prices Shares (years) Price Shares Price $ 0.32 - $10.56 372,825 9.89 $ 10.56 191,392 $ 10.56 $19.20 - $22.72 60,647 9.24 $ 18.87 22,416 $ 19.42 $25.60 - $32.00 95,694 7.65 $ 29.83 82,289 $ 29.69 $35.52 - $49.60 35,003 7.41 $ 42.11 31,481 $ 41.46 $52.48 - $71.04 111,644 7.87 $ 58.22 108,779 $ 58.12 675,812 8.89 $ 43.52 436,357 $ 28.71 As of December 31, 2016, there were approximately $ 2.7 4.2 The Company used the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options issued for the year ended December 31, 2016 was estimated at the grant date using the following weighted average assumptions: Dividend yield 0 87.50 2.250 9.17 The total stock option-based compensation recorded as operating expense was $ 2,804,527 922,934

Common and Preferred Stock Rese

Common and Preferred Stock Reserved for Future Issuances:	12 Months Ended
	Dec. 31, 2016
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Common And Preferred Stock Reserved For Future Issuances [Text Block]	Note 9 – Common and Preferred Stock Reserved for Future Issuances : Common Stock Reserved Common stock warrants outstanding 6,009,366 Common stock options outstanding 675,812 Total 6,685,178 On February 9, 2015, the holders of placement agent warrants to purchase an aggregate of 1,325,000 41,416 As of December 31, 2016, the Company is no longer required to reserve shares of Common Stock to accommodate up to an additional 50 Based upon the November 2016 Private Placement, the holders of 811,799 372,825 150

Subsequent Events_

Subsequent Events:	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 10 – Subsequent Events : Compensation Recommendation On January 4, 2017, based upon a recommendation by the compensation committee of the board of directors, the Company established the compensation for Dr. Daniel Alkon, M.D., who has served as President of the Company since September 23, 2016 and as the Company’s Chief Scientific Officer since August 2013. In consideration for his service as President, Dr. Alkon shall receive a salary of $ 25,000 75,000 Reverse Stock Split On January 11, 2017, the Company effected a 1-for-32 400,000,000 12,500,000 On February 17, 2017, the stockholders of the Company approved to increase the number of authorized shares of the Company’s Common Stock to 150 On January 19, 2017, the Company entered into a second license agreement with Stanford, pursuant to which Stanford has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of “Bryostatin Compounds and Methods of Preparing the Same,” or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents. The Company paid Stanford $ 70,000 10,000 2.1 1.5 4.5 Warrant Exercises From January 1, 2017 through March 6, 2017, 78 holders of 686,275 0.32 686,275

Summary of Significant Accoun17

Summary of Significant Accounting Policies: (Policies)	12 Months Ended
	Dec. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents: The Company considers all highly liquid temporary cash investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2016, the Company’s cash balances exceed the current insured amounts under the Federal Deposit Insurance Corporation.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment: December 31, December 31, 2016 2015 Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (14,518) (7,595) Property and equipment, net $ 55,198 $ 59,175 Depreciation expense for the years ended December 31, 2016 and 2015 was $ 6,923 6,270
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs: All research and development costs, including costs to maintain or expand the Company’s patent portfolio licensed from CRE that do not meet the criteria for capitalization are expensed when incurred. FASB ASC Topic 730 requires companies involved in research and development activities to capitalize non-refundable advance payments for such services pursuant to contractual arrangements because the right to receive those services represents an economic benefit. Such capitalized advances will be expensed when the services occur and the economic benefit is realized. There were no capitalized research and development services at December 31, 2016 and 2015.
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share: Basic earnings (loss) per common share amounts are based on weighted average number of common shares outstanding. Diluted earnings per share amounts are based on the weighted average number of common shares outstanding, plus the incremental shares that would have been outstanding upon the assumed exercise of all potentially dilutive stock options and warrants subject to anti-dilution limitations. All such potentially dilutive instruments were anti-dilutive as of December 31, 2016 and 2015. At December 31, 2016 and 2015, the number of shares underlying options and warrants that were anti-dilutive were approximately $ 6.9 4.5
Income Tax, Policy [Policy Text Block]	Income Taxes: Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently due and deferred taxes. Deferred taxes are recognized for differences between the basis of assets and liabilities for financial statement and income tax purposes and the tax effects of net operating loss and other carryforwards. The deferred tax assets and liabilities represent the future tax consequences of those differences and carryforwards, which will either be taxable or deductible when the related assets, liabilities or carryforwards are recovered or settled. Deferred tax assets are reduced by a valuation allowance when, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company applies the provisions of FASB ASC 740-10, Accounting for Uncertain Tax Positions The Company has concluded that there are no significant uncertain tax positions requiring recognition in the accompanying financial statements. The tax period that is subject to examination by major tax jurisdictions for generally three years from the date of filing.
Income Tax Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties: The Company operates in an industry that is subject to rapid technological change, intense competition and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory and other risk. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the ability to obtain favorable licensing, manufacturing or other agreements for its product candidates and the ability to raise capital to achieve strategic objectives.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Compensation: The Company accounts for stock-based awards to employees in accordance with applicable accounting principles, which requires compensation expense related to share-based transactions, including employee stock options, to be measured and recognized in the financial statements based on a determination of the fair value of the stock options. The grant date fair value is determined using the Black-Scholes-Merton (“Black-Scholes”) pricing model. Employee stock option expense is recognized over the employee’s requisite service period (generally the vesting period of the equity grant). The Company’s option pricing model requires the input of highly subjective assumptions, including the expected stock price volatility, expected term, and forfeiture rate. Any changes in these highly subjective assumptions significantly impact stock-based compensation expense. Options awarded to purchase shares of common stock issued to non-employees in exchange for services are accounted for as variable awards in accordance with applicable accounting principles. Such options are valued using the Black-Scholes option pricing model.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements: In February 2016, the FASB issued ASU No. 2016-02, Leases In March 2016, the FASB issued ASU No. 2016-09, Stock Compensation

Summary of Significant Accoun18

Summary of Significant Accounting Policies: (Tables)	12 Months Ended
	Dec. 31, 2016
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment is capitalized and depreciated on a straight line basis over the useful life of the asset, which is deemed to be between three and ten years. Property and equipment consist of the following: December 31, December 31, 2016 2015 Property and equipment $ 69,716 $ 66,770 Accumulated depreciation (14,518) (7,595) Property and equipment, net $ 55,198 $ 59,175

Stock Options_ (Tables)

Stock Options: (Tables)	12 Months Ended
	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following is a summary of stock option activity under the stock option plans for the year ended December 31, 2016: Weighted- Average Weighted- Remaining Aggregate Average Contractual Intrinsic Number of Exercise Term Value Shares Price (Years) (in thousands) Options outstanding at January 1, 2016 268,217 $ 42.24 7.5 $ 0 Options granted 424,390 $ 11.56 Less options forfeited (16,170) $ 20.29 Less options expired/cancelled (625) $ 56.32 Less options exercised - $ - Options outstanding at December 31, 2016 675,812 $ 23.54 8.9 $ 0 Options exercisable at December 31, 2016 436,357 $ 28.71 8.3 $ 0
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following is a summary of stock options outstanding under the plans as of December 31, 2016: Stock Options Stock Options Outstanding Exercisable Weighted Avg. Weighted Avg. Weighted Avg. Range of Number of Contractual Life Exercise Number of Exercise Exercise Prices Shares (years) Price Shares Price $ 0.32 - $10.56 372,825 9.89 $ 10.56 191,392 $ 10.56 $19.20 - $22.72 60,647 9.24 $ 18.87 22,416 $ 19.42 $25.60 - $32.00 95,694 7.65 $ 29.83 82,289 $ 29.69 $35.52 - $49.60 35,003 7.41 $ 42.11 31,481 $ 41.46 $52.48 - $71.04 111,644 7.87 $ 58.22 108,779 $ 58.12 675,812 8.89 $ 43.52 436,357 $ 28.71

Common and Preferred Stock Re20

Common and Preferred Stock Reserved for Future Issuances: (Tables)	12 Months Ended
	Dec. 31, 2016
Common And Preferred Stock Reserved For Future Issuances [Abstract]
Schedule of Guarantor Obligations [Table Text Block]	Common stock reserved for future issuances consisted of the following at December 31, 2016 giving effect to the November 2016 Private Placement and February 17, 2017 shareholder vote described below: Common Stock Reserved Common stock warrants outstanding 6,009,366 Common stock options outstanding 675,812 Total 6,685,178

Organization and Nature of Pl21

Organization and Nature of Planned Business: (Details Textual) - USD ($) $ / shares in Units, $ in Millions	Mar. 06, 2017	Dec. 31, 2016	Dec. 31, 2015
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Subsequent Event [Member]
Cash, Cash Equivalents, and Short-term Investments	$ 24.1

Summary of Significant Accoun22

Summary of Significant Accounting Policies: (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment	$ 69,716	$ 66,770
Accumulated depreciation	(14,518)	(7,595)
Property and equipment, net	$ 55,198	$ 59,175

Summary of Significant Accoun23

Summary of Significant Accounting Policies: (Details Textual) - USD ($) shares in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Depreciation, Depletion and Amortization	$ 6,923	$ 6,270
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6.9	4.5
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Contractual Commitments_ (Detai

Contractual Commitments: (Details Textual)	1 Months Ended	12 Months Ended
	Aug. 31, 2016USD ($)shares	Dec. 31, 2016USD ($)	Sep. 04, 2014USD ($)ft²
Contractual Commitments And Contingencies [Line Items]
Area of Land | ft²			4,000
Description of Lessor Leasing Arrangements, Operating Leases		The lease commenced on September 1, 2014 and expires on December 1, 2017 and has two (2) one-year renewal options.
Accrued Rent			$ 88,000
Operating Leases, Future Minimum Payments, Remainder of Fiscal Year		$ 136,100
SM Capital Management LLC [Member]
Contractual Commitments And Contingencies [Line Items]
Management Fee Payable	$ 10,000
Monthly Consulting Fee Installments Payable	$ 120,000
Chief Executive Officer [Member]
Contractual Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Management Fee Payable	$ 50,000
Supplemental Unemployment Benefits, Severance Benefits	$ 200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares	21,877
Management [Member]
Contractual Commitments And Contingencies [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares | shares	18,738
Maximum [Member]
Contractual Commitments And Contingencies [Line Items]
Increase (Decrease) in Accrued Salaries	$ 23,333
Minimum [Member]
Contractual Commitments And Contingencies [Line Items]
Increase (Decrease) in Accrued Salaries	$ 10,000

Collaborative Agreements_ (Deta

Collaborative Agreements: (Details Textual) - USD ($)	Nov. 11, 2015	Oct. 09, 2015	May 15, 2014	Jun. 30, 2016	Nov. 19, 2014	Dec. 31, 2016
Collaborative Agreements [Line Items]
Estimated Budget For Services		$ 11,600,000
Payments for Advance to Affiliate	$ 1,875,861	$ 200,000
Service Fees	928,000
Pass Through Expenses	268,000
Investigator And Institute fees	680,000
Clinical Trial, Amended Protocol, Cost savings						$ 2,000,000
July 2016 Through September 2017 [Member]
Collaborative Agreements [Line Items]
Estimated Budget For Services	$ 9,500,000
Contract Research Organization [Member]
Collaborative Agreements [Line Items]
Commitment To Pay Fees			$ 715,159	$ 150,000
Reduction Of Commitment Fees					$ 657,238
Payments for Fees				$ 837,112
Worldwide Clinical Trials [Member]
Collaborative Agreements [Line Items]
Prepaid Expense						1,600,000
Stanford Agreement [Member]
Collaborative Agreements [Line Items]
Annual License Maintenance Fee						10,000
Mount Sinai Agreement [Member]
Collaborative Agreements [Line Items]
License Initiation Fee						$ 39,200

Related Party Transactions an26

Related Party Transactions and Licensing / Research Agreements: (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 12, 2015	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Technology Services Costs			$ 2,052,595
Research and Development Expense, Total		$ 5,603,989	2,180,263
Due to Related Parties, Current		4,609	$ 389,058
BRNI License Agreement [Member]
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 1,166,666
Service Fees Third Party	$ 83,333
Due to Related Parties		14,558
November 2015 Sow Agreement [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Purchases from Related Party		1,000,000
Blanchette Rockefeller Neurosciences Institute [Member]
Related Party Transaction [Line Items]
Royalties Percentage	5.00%
Post PA Fee Proceeds Percent	2.50%
Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Research and Development Expense, Total		$ 1,000,000
Services Reimbursement [Member]
Related Party Transaction [Line Items]
Royalties Percentage		5.00%
Services Reimbursement [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Royalties Percentage		2.00%
Services Reimbursement [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Royalties Percentage		5.00%
Series B Preferred Stock [Member] | Fixed Research Fee [Member]
Related Party Transaction [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 25,000,000
President [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		3.90%

Income Taxes_ (Details Textual)

Income Taxes: (Details Textual) $ in Millions	50 Months Ended
	Dec. 31, 2016USD ($)
Income Tax Expenses Benefit [Line Items]
Operating Income (Loss)	$ 32.5
Deferred Tax Assets, Gross, Current	11
Deferred Tax Assets, Net	$ 1.1

Common Stock_ (Details Textual)

Common Stock: (Details Textual) - USD ($)	1 Months Ended				12 Months Ended
	Nov. 30, 2016	Nov. 23, 2016	Nov. 18, 2016	Nov. 17, 2016	Dec. 31, 2016	Dec. 31, 2015	Feb. 17, 2017	Jan. 02, 2017
Class of Stock [Line Items]
Common Stock, Shares Authorized					12,500,000	12,500,000
Deemed Dividend Payable			$ 9,400,000		$ 9,396,311	$ 0
Series A Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.32
Series C Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			0.32
Series E Warrant [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 32
November 2016 Private Placement [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 12.80
Stock Issued During Period, Shares, New Issues	3,828,754
Shares Issued, Price Per Share	$ 6.40
Proceeds from Issuance of Private Placement	$ 24,500,000
Class Of Warrant Or Right, Expiration Term	5 years
Placement Agency Agreement [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 6.40
Proceeds from Issuance of Private Placement		$ 10,000,000
Class Of Warrant Or Right, Expiration Term				5 years
Private placement Agent Fee Percentage				10.00%
Warrant To Purchase Common Stock Percentage				10.00%
Placement Agency Agreement [Member] | Series B Broker Warrants [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.32
Class Of Warrant Or Right, Expiration Term		6 months
Class of Warrant or Right, Outstanding		70,119
Placement Agency Agreement [Member] | Series A Broker Warrants [Member]
Class of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.32
Class of Warrant or Right, Outstanding		41,416
Subsequent Event [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized							150,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								686,275
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.32
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted					262,349.4
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.0001
Series B COD Amendment [Member] | November 2016 Private Placement [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted				255,450.4
Convertible Preferred Stock, Shares Issued upon Conversion				825,812
Proceeds from Issuance of Private Placement				$ 8,000,000
Common Stock Conversion Price				$ 18.56
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues					3,828,754
Neurotrope Inc. [Member] | Common Stock [Member]
Class of Stock [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion					847,371
Warrants Exercisable					541,189
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					541,189
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.32

Stock Options_ (Details)

Stock Options: (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding	268,217
Number of Shares, Options granted	424,390
Number of Shares, Less options forfeited	(16,170)
Number of Shares, Less options expired/cancelled	(625)
Number of Shares, Less options exercised	0
Number of Shares, Outstanding	675,812	268,217
Number of Shares, Options exercisable	436,357
Weighted-Average Exercise Price, Outstanding	$ 42.24
Weighted-Average Exercise Price, Options granted	11.56
Weighted - Average Exercise Price, Options terminated	20.29
Weighted-Average Exercise Price, Options, Less options expired/cancelled	56.32
Weighted-Average Exercise Price, Options exercised	0
Weighted-Average Exercise Price, Outstanding	23.54	$ 42.24
Weighted-Average Exercise Price, Options exercisable	$ 28.71
Weighted-Average Remaining Contractual Term, Outstanding (in years)	8 years 10 months 24 days	7 years 6 months
Weighted-Average Remaining Contractual Term, Exercisable (in years)	8 years 3 months 18 days
Aggregate Intrinsic Value, Outstanding	$ 0	$ 0
Aggregate Intrinsic Value, Exercisable	$ 0

Stock Options_ (Details 1)

Stock Options: (Details 1) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	675,812	268,217
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	8 years 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 23.54	$ 42.24
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	436,357
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 28.71
Exercise Price Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	0.32
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 10.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	372,825
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 10 months 20 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 10.56
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	191,392
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 10.56
Exercise Price Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	19.20
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 22.72
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	60,647
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	9 years 2 months 26 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 18.87
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	22,416
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 19.42
Exercise Price Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	22.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 32
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	95,694
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 7 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 29.83
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	82,289
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 29.69
Exercise Price Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	35.52
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 49.60
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	35,003
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 4 months 28 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 42.11
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	31,481
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 41.46
Exercise Price Range Five [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit	52.48
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit	$ 71.04
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	111,644
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 10 months 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 58.22
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	108,779
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$ 58.12

Stock Options_ (Details Textual

Stock Options: (Details Textual) - USD ($)	Aug. 04, 2016	Jul. 23, 2014	Dec. 31, 2016	Dec. 31, 2015	Aug. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			87.50%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			2.25%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 9.17
Employee Benefits and Share-based Compensation			$ 2,804,527	$ 722,934
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options			$ 2,700,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			4 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost	$ 500,000
Management [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares					18,738
Management [Member] | Separation Agreements [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares	40,511
Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			218,750
Equity Incentive Plan 2013 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		312,500
Equity Incentive Plan 2013 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period		93,750
Equity Incentive Plan Amendment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			685,325

Common and Preferred Stock Re32

Common and Preferred Stock Reserved for Future Issuances: (Details)	Dec. 31, 2016shares
Class of Stock [Line Items]
Common Stock Reserved	6,685,178
Common stock warrants outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	6,009,366
Common stock options outstanding [Member]
Class of Stock [Line Items]
Common Stock Reserved	675,812

Common and Preferred Stock Re33

Common and Preferred Stock Reserved for Future Issuances: (Details Textual) - shares	Feb. 09, 2015	Dec. 31, 2016	Dec. 31, 2015	Feb. 17, 2017
Percentage of shares Reserved for Potential Dilution		50.00%
Conversion of Stock, Shares Issued		11,814,874	18,524,163
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance		675,812	268,217
Common Stock, Shares Authorized		12,500,000	12,500,000
Subsequent Event [Member]
Common Stock, Shares Authorized				150,000,000
Nov 2016 Private Placement [Member]
Class of Warrant or Right, Outstanding		811,799
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance		372,825
Warrant Holder [Member]
Conversion of Stock, Shares Issued	41,416
Series A Preferred Stock [Member] | Warrant Holder [Member]
Conversion of Stock, Shares Converted	1,325,000

Subsequent Events_ (Details Tex

Subsequent Events: (Details Textual) - USD ($)	Jan. 11, 2017	Jan. 04, 2017	Jan. 02, 2017	Jan. 19, 2017	Dec. 31, 2016	Feb. 17, 2017	Dec. 31, 2015
Subsequent Event [Line Items]
Common Stock, Shares Authorized					12,500,000		12,500,000
Scenario, Previously Reported [Member]
Subsequent Event [Line Items]
Common Stock, Shares Authorized					400,000,000
Stanford Agreement [Member]
Subsequent Event [Line Items]
Annual License Maintenance Fee					$ 10,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			686,275
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.32
Stockholders' Equity, Reverse Stock Split	1-for-32
Common Stock, Shares Authorized						150,000,000
Stock Issued During the Period, Stock Warrants Exercised			686,275
Subsequent Event [Member] | Stanford Agreement [Member]
Subsequent Event [Line Items]
Annual License Maintenance Fee				$ 10,000
Commitment To Pay Fees				2,100,000
License Costs				$ 70,000
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Royalty Payment Percentage				4.50%
Subsequent Event [Member] | Minimum [Member]
Subsequent Event [Line Items]
Royalty Payment Percentage				1.50%
President [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Compensation		$ 25,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount		$ 75,000